SAB Biotherapeutics (NASDAQ:SABS) Shares Up 3.8%

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) shot up 3.8% during mid-day trading on Tuesday . The company traded as high as $4.50 and last traded at $4.09. 14,549 shares traded hands during trading, an increase of 4% from the average session volume of 13,979 shares. The stock had previously closed at $3.94.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Chardan Capital reiterated a “buy” rating and issued a $25.00 target price on shares of SAB Biotherapeutics in a research note on Tuesday, April 16th. HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of SAB Biotherapeutics in a research note on Tuesday, April 16th.

SAB Biotherapeutics Trading Up 3.8 %

The company has a current ratio of 5.45, a quick ratio of 5.45 and a debt-to-equity ratio of 0.06. The company’s fifty day simple moving average is $4.61 and its 200-day simple moving average is $3.49.

Hedge Funds Weigh In On SAB Biotherapeutics

Several institutional investors have recently bought and sold shares of the business. Pathstone Family Office LLC purchased a new position in shares of SAB Biotherapeutics in the 3rd quarter valued at $319,000. Commodore Capital LP purchased a new position in SAB Biotherapeutics in the fourth quarter valued at about $1,259,000. BVF Inc. IL purchased a new position in SAB Biotherapeutics in the fourth quarter valued at about $6,310,000. Finally, RTW Investments LP bought a new position in SAB Biotherapeutics in the fourth quarter worth about $6,310,000. 7.82% of the stock is owned by hedge funds and other institutional investors.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.